Rapid expansion in clinical applications, rising demand for genomic diagnostics, and increased investment in CRISPR-based ...

The collaboration pairs Mimulus's molecular architecture with GenScript's massive synthesis scale to liberate critical grid power for AI compute and launch the "Forever Archive" for enterprise data ...

PISCATAWAY, N.J. and LOS ANGELES, April 9, 2026 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of CMOS-based DNA synthesis technologies, and Mimulus Corp, the pioneer in ...

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

The issuer is solely responsible for the content of this announcement. BRAIN Biotech has been granted a key patent for its CRISPR-BMC genome-editing technology Newly patented CRISPR nuclease exhibits ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Fri, April 3, 2026 at 12:52 PM UTC What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and shovels -- data that makes those cures ...

The precision medicine market is forecast to grow 16.3% annually to $249.24B by 2030, creating a natural flywheel where Illumina’s sequencing data enables CRISPR’s more precise gene edits, which ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.